13 reports of this reaction
0.4% of all ACTIVATED CHARCOAL reports
#79 most reported adverse reaction
REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME is the #79 most commonly reported adverse reaction for ACTIVATED CHARCOAL, manufactured by Padagis US LLC. There are 13 FDA adverse event reports linking ACTIVATED CHARCOAL to REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME. This represents approximately 0.4% of all 3,053 adverse event reports for this drug.
ACTIVATED CHARCOAL has an overall safety score of 85 out of 100. Patients taking ACTIVATED CHARCOAL who experience reversible cerebral vasoconstriction syndrome should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME is a less commonly reported adverse event for ACTIVATED CHARCOAL, but still significant enough to appear in the safety profile.
In addition to reversible cerebral vasoconstriction syndrome, the following adverse reactions have been reported for ACTIVATED CHARCOAL:
REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME has been reported as an adverse event in 13 FDA reports for ACTIVATED CHARCOAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME accounts for approximately 0.4% of all adverse event reports for ACTIVATED CHARCOAL, making it a notable side effect.
If you experience reversible cerebral vasoconstriction syndrome while taking ACTIVATED CHARCOAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.